You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA216
  • Published:  23 February 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Leukaemia (lymphocytic) - bendamustine: patient group, professional group and NHS organisation submissions

  • Leukaemia (lymphocytic) - bendamustine: British Society for Haematology and Royal College of Pathologists (joint submission)

  • Leukaemia (lymphocytic) - bendamustine: Chronic Lymphocytic Leukaemia Support Association

  • Leukaemia (lymphocytic) - bendamustine: Leukaemia CARE

  • Leukaemia (lymphocytic) - bendamustine: Lymphoma Association

  • Leukaemia (lymphocytic) - bendamustine: Royal College of Physicians / NCRI / RCR / ACP / JCCO

  • Leukaemia (lymphocytic) - bendamustine: United Kingdom Chronic Lymphocytic Leukaemia Forum


This page was last updated: 17 December 2010

Back to top